Posted by Michael Wonder on 24 Feb 2022
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Ontario, Manitoba and New Brunswick
24 February 2022 - Private insurance coverage across Canada exceeds 90%.
Valeo Pharma is proud to announce another major milestone for its two innovative Asthma therapies; Enerzair Breezehaler and Atectura Breezhaler, which have been accepted for reimbursement by the Ontario Drug Benefit program, the Manitoba Pharmacare Program, the New Brunswick Drug plan, and the NIHB and VAC federal programs.
The public reimbursements are now in effect with the exception of the Ontario listing which takes effect on 28 February 2022. These listings are now published on the Ontario Drug Benefit Formulary, the Manitoba Drug Benefits Formulary and New Brunswick Drug Plans Formulary.
